69
Views
2
CrossRef citations to date
0
Altmetric
Articles

UNDULANT COURSE OF AFP: A Sign of Tumor Activation or Not?

, MD, , MD & , MD
Pages 30-35 | Received 03 Oct 2007, Accepted 10 Mar 2008, Published online: 09 Jul 2009

REFERENCES

  • Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, et al. Pediatric Oncology Group 9049; Children's Cancer Group 8882. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004; 22: 2691–2700
  • Cushing B, Perlman EJ, Marina NM, Castleberry RP. Germ cell tumors. Principles and Practice of Pediatric Oncology, 5 ed., PA Pizzo, DG Poplack. Lippincott Williams & Wilkins, Philadelphia 2006; 1116–1138
  • Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000; 88: 162–168
  • Flechon A, Culine S, Theodore C, Droz JP. Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol. 2005; 48: 957–963
  • Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000; 163: 796–801
  • Wu JT, Book L, Sudar K. Serum α-fetoprotein (AFP) levels in normal infants. Pediatr Res. 1981; 15: 50–52

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.